Processing the protocol with id 139
##########################################
Searching for the item "2a Scientific background and explanation of rationale..."
This part was defined, probably, at this section: 1.0 Introduction 
For more information about the rationales, go to sections:
1.1 Background and Rationale 
1.1.3 Rationale for the Use of DOXIL/CAELYX 
1.1.4 Rationale for the Use of Topotecan 
I have not found anything about the previous studies from titles, lets take a look for the introduction
Previous studies: FOUND
Occurrences in the text:
17059	Phase I 	"... 3: March 26, 2001  In two separate Phase I dose escalation studies, 56..."
14597	clinical studies with	"... affecting normal tissue. 13  On going clinical studies with DOXIL/CAELYX..."
17912	Phase II 	"... Of 35 patients  enrolled in a Phase II study in which DOXIL/CAELYX..."
17739	clinical activity	"... based on tumor markers.  Substantial clinical activity has been demonstrated..."
##########################################
Searching for the item "2b Specific objectives or hypotheses"...
This part was defined, probably, at this section: 1.2 Objective 
Primary objectives: NOT FOUND
Secondary objectives: NOT FOUND
Objectives: FOUND
Occurrences in the text:
20753	compare 	"... s to compare the efficacy and safety of DOXIL/CAELYX  versus topotecan HCl in patients with epithelial..."
##########################################
Searching for the item "3a Description of trial design (such as parallel, factorial) including allocation ratio"...
This part was defined, probably, at this section: 1.3 Study Design 
I found the following features of the study:
open label
randomized
9 CONFIDENTIAL  Doxorubicin HCl Liposome Injection  SEQUUS Pharm
prospective
Placebo: NOT FOUND -> active-controlled study?
Allocation ratio: NOT FOUND
##########################################
Checking for the item "4a Eligibility criteria for participants..."
This part was defined, probably, at this section: 2.0 Patient Enrollment 
I have found: exclusion criteria, inclusion criteria
##########################################
Checking for the item "5 Interventions for each group with sufficient details to allow replication, including how and when they were actually administered"
This part was defined, probably, at this section: 4.0 Administration of Study Drug 
##########################################
Checking for the item “7a how sample size was determined”...
This part was defined, probably, at this section: 8.6.7 Statistical Power and Sample Size Considerations 
##########################################
Searching any information about a randomzation
This part was defined, probably, at this section: 2.4 Randomization 
Maybe this information will be interesting:
2551	will be randomized	"... nd evaluable  disease, who have received no more than one prior regimen, which was platinum based,  will be randomized to receive either a one hour intravenous infusion of  DOXIL/CAELYX, 50 mg/m2..."
##########################################
Checking for the item “11a  if done, who was blinded after assignment to interventions (eg, participants, care providers, those assessing outcomes) and how.”
Unfortunately, I could not find this part, maybe, due to bad conversion to txt file!
##########################################
Checking for the item “12a  statistical methods used to compare groups for primary and secondary outcomes”
This part was defined, probably, at this section: 8.6 Data Analysis And Statistical Consideration 
This part was defined, probably, at this section: 8.6.1 Data Analysis 
I found the following methods:
60724 	 log rank 	 "... volving the treatment group. Stratified log rank test (stratified by  platinum..."
62158 	 log rank 	 "... s will be compared using the stratified log rank  test as a primary analysis...."
63244 	 log rank 	 "... .4 Duration of Response  The stratified log rank statistic will be used for..."
69778 	 log rank 	 "... m analyses is time to progression.  The log rank test stratified for platinum..."
160674 	 log rank 	 "... dose and schedule in the protocol.  The log rank test stratified for platinum..."
69002 	 fleming 	 "... udy for at least 6 months.  The O Brien Fleming type spending function was..."
69423 	 fleming 	 "... planned to be terminated if the O Brien Fleming  boundary is crossed at any of..."
158278 	 fleming 	 "... dy for at least 6  months.  The O Brien Fleming type spending function was..."
158701 	 fleming 	 "... lanned to be terminated if the  O Brien Fleming boundary is crossed at any of..."
159192 	 fleming 	 "... ed in the EaSt software33 with  O Brien Fleming type spending function was..."
60417 	 cochran mantel haenszel 	 "... egorical data will be tested  using the Cochran Mantel Haenszel (CMH) tests,..."
62981 	 cochran mantel haenszel 	 "... tment groups will be  conducted using a Cochran Mantel Haenszel analysis..."
70336 	 cochran mantel haenszel 	 "... p differences  will be tested using the Cochran Mantel Haenszel (CMH) test,..."
161234 	 cochran mantel haenszel 	 "... p differences will be tested using the  Cochran Mantel Haenszel (CMH) test,..."
62223 	 wilcoxon 	 "... ry analysis. The stratified generalized Wilcoxon test will also be provided. ..."
63404 	 wilcoxon 	 "... responders. The stratified generalized  Wilcoxon test will also be provided. ..."
62080 	 kaplan meier 	 "... estimated for each treatment using the  Kaplan Meier method. The two treatments..."
